Editors Note:

This sector is healing and a breakout over resistance is imminent. Despite negative comments about drug prices from the Trump administration, the biotech sector is rising.



NEW DIRECTIONAL CALL PLAYS

XBI - Biotech ETF - ETF Profile

The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index.

This is a sector ETF that tracks 90 biotech and pharma stocks having a market cap of at least $500 million. The index is rebalanced quarterly to remove stocks that have decreased and add stocks that have exceeded the market cap requirements. As such this ETF is focused on the larger cap names and many of the small cap stocks are not represented.

The XBI has rebounded from $61, where it fell after comments from the president in January, to $67 despite new comments earlier this week. The overall optimism about the economy, faster approval of drugs and tax cuts have lifted the sector.

If the ETF can move over $70 the next material resistance is $80. I am using an inexpensive March option because the sector can be volatile. There are no April options yet.

Buy Mar $68 call, currently $1.86, initial stop loss $63.85.


NEW DIRECTIONAL PUT PLAYS

No New Bearish Plays